Cargando…

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldo, Aline, Leunda, Amaya, Willemarck, Nicolas, Pauwels, Katia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147846/ https://www.ncbi.nlm.nih.gov/pubmed/34063733 http://dx.doi.org/10.3390/vaccines9050453

Ejemplares similares

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations
por: Leunda, Amaya, et al.
Publicado: (2014)

Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment
por: Onnockx, Sheela, et al.
Publicado: (2023)

Laboratory activities involving transmissible spongiform encephalopathy causing agents: Risk assessment and biosafety recommendations in Belgium
por: Leunda, Amaya, et al.
Publicado: (2013)

General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination
por: Baldo, Aline, et al.
Publicado: (2013)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Viral Vector Vaccines against Bluetongue Virus
por: Jiménez-Cabello, Luis, et al.
Publicado: (2020)

Recombinant viral hemorrhagic septicemia virus with rearranged genomes as vaccine vectors to protect against lethal betanodavirus infection
por: Souto, Sandra, et al.
Publicado: (2023)

Viral Vector Vaccines Against ASF: Problems and Prospectives
por: Ravilov, Rustam Kh., et al.
Publicado: (2022)

Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1
por: Mendes, Érica Araújo, et al.
Publicado: (2013)

Development of novel SARS-CoV-2 viral vectors
por: Liu, Huan, et al.
Publicado: (2023)

Retroviral Vectors for Analysis of Viral Mutagenesis and Recombination
por: Rawson, Jonathan M.O., et al.
Publicado: (2014)

Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Viral vector vaccines
por: McCann, Naina, et al.
Publicado: (2022)

Recombinant vector vaccine evolution
por: Bull, James J., et al.
Publicado: (2019)

Recombinant Vectors as Influenza Vaccines
por: Kopecky-Bromberg, Sarah A., et al.
Publicado: (2009)

A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2
por: Rohaim, Mohammed A., et al.
Publicado: (2020)

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination
por: Baldo, Aline, et al.
Publicado: (2015)

Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus
por: López-Camacho, César, et al.
Publicado: (2019)

Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice
por: Lu, Mingqing, et al.
Publicado: (2022)

Viral vectored transmission blocking vaccines against Plasmodium falciparum
por: Kapulu, Melissa C, et al.
Publicado: (2010)

Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2
por: Madonov, P. G., et al.
Publicado: (2021)

Production and Titering of Recombinant Adeno-associated Viral Vectors
por: McClure, Christina, et al.
Publicado: (2011)

Gallid herpesvirus 3 SB-1 strain as a recombinant viral vector for poultry vaccination
por: Sadigh, Yashar, et al.
Publicado: (2018)

Viral vectors for vaccine applications
por: Choi, Youngjoo, et al.
Publicado: (2013)

Viral Vectors for Veterinary Vaccines
por: Sheppard, Michael
Publicado: (1999)

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models
por: Ku, Min-Wen, et al.
Publicado: (2021)

BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers
por: Mustafa, Abu Salim
Publicado: (2020)

Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
por: Milicic, Anita, et al.
Publicado: (2017)

Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis
por: Ferreira, Raphaella D., et al.
Publicado: (2022)

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
por: Ebrahimi, Narges, et al.
Publicado: (2023)

Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission
por: Ye, Chengjin, et al.
Publicado: (2023)

Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection
por: Liao, Po-Wei, et al.
Publicado: (2021)

Manufacturing of recombinant adeno-associated viral vectors for clinical trials
por: Clément, Nathalie, et al.
Publicado: (2016)

SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
por: Füessl, Louise, et al.
Publicado: (2022)

Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens
por: LeCureux, Jonathan S., et al.
Publicado: (2018)

Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
por: Chang, Aiquan, et al.
Publicado: (2022)

Humoral response to heterologous prime‐booster vaccination in heart transplant recipients aged 18–70 years primed with a viral vector SARS‐CoV‐2 vaccine
por: Tanner, Richard, et al.
Publicado: (2022)

Evolution and containment of transmissible recombinant vector vaccines
por: Nuismer, Scott L., et al.
Publicado: (2019)

Vaccines against SARS-COV-2
por: Kim, Jerome H.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i6en853kfmec26frj0hukbutd6